Herantis Nears Key Parkinson's Trial, Aiming to Halt the Disease Itself

ESPOO, FINLAND – June 02, 2026 – In the relentless global search for a therapy that can do more than just mask the symptoms of Parkinson’s disease, Finnish biotech firm Herantis Pharma has just cleared a critical hurdle. The company announced today that it received positive feedback from the U.S. Food and Drug Administration (FDA) on the design of its upcoming Phase 2a clinical trial for HER-096, a promising drug candidate aimed at modifying the course of the neurodegenerative disorder.

This development is more than just a procedural milestone; it represents a significant validation of the company's scientific approach and a beacon of hope for the millions living with Parkinson's. With the trial design now finalized and key partners in place, Herantis is moving closer to answering the pivotal question: can HER-096 actually slow or stop the devastating progression of the disease?

A New Mechanism to Protect and Restore

For decades, the standard of care for Parkinson's has centered on replacing dopamine, the neurotransmitter lost as the disease destroys specific neurons in the brain. Treatments like levodopa are effective at managing motor symptoms like tremors and stiffness, but they do nothing to stop the underlying cell death. Over time, their efficacy wanes, and they can introduce debilitating side effects. The holy grail of Parkinson's research has thus been a “disease-modifying therapy” (DMT)—a treatment that protects neurons from dying in the first place.

This is precisely where HER-096 aims to break new ground. The drug is a first-in-class small peptide engineered to mimic the function of a naturally occurring protein called cerebral dopamine neurotrophic factor (CDNF). In the healthy brain, CDNF acts as a potent survival factor for dopamine-producing neurons, protecting them from stress and helping them function correctly. The challenge has always been that the CDNF protein itself is too large to cross the blood-brain barrier, the highly selective membrane that protects the brain, making direct therapeutic use impractical without invasive delivery methods.

Herantis's innovation with HER-096 is twofold. First, it has created a much smaller molecule that retains the critical neuroprotective functions of CDNF. Second, and crucially, this peptide is designed to efficiently cross the blood-brain barrier after a simple subcutaneous injection, a route of administration similar to an insulin shot. Positive results from a Phase 1b trial already confirmed the drug was generally safe and well-tolerated, but also provided biomarker evidence that it was reaching the brain and engaging its biological targets.

The Regulatory Path and Trial Design

The feedback from the FDA, stemming from a pre-Investigational New Drug (IND) meeting, is a powerful endorsement. The agency deemed the proposed Phase 2a study design “appropriate” and raised no red flags concerning the company’s manufacturing processes or extensive preclinical data. This effectively gives Herantis a green light to proceed with confidence and confirms it could activate U.S. clinical sites in the future, expanding its global research footprint.

The now-finalized Phase 2a study is a meticulously designed proof-of-concept trial. It will be a randomized, double-blind, placebo-controlled study—the gold standard for clinical research—enrolling approximately 100 newly diagnosed Parkinson’s patients across multiple sites in Europe. A key detail is that these patients will not yet be on symptomatic medication, allowing for a clearer assessment of HER-096’s direct effects on disease progression. Participants will receive twice-weekly subcutaneous injections of either the drug or a placebo for six months. Following this period, all patients will have the opportunity to receive HER-096 in a six-month open-label extension, ensuring all participants eventually get access to the investigational therapy.

To execute this complex trial, Herantis has appointed CTC Clinical Trial Consultants AB, a clinical research organization with deep expertise in Parkinson's disease studies, to manage site operations and ensure rigorous execution.

The Digital Revolution in Measuring Parkinson's

Perhaps one of the most forward-looking aspects of the upcoming trial is its primary endpoint: a Digital Motor Score (DMS). This marks a significant shift away from traditional, more subjective clinical rating scales, which are typically administered by a clinician during infrequent clinic visits. Such assessments provide only a brief snapshot of a patient's condition, which can fluctuate significantly day-to-day.

In contrast, the DMS will be captured using a digital biomarker platform from Swiss medtech partner Indivi. This technology leverages smartphone-based assessments to continuously and objectively measure subtle changes in a patient's motor and cognitive functions in their real-world environment. By gathering high-frequency, objective data, Herantis hopes to gain a much more sensitive and accurate picture of how HER-096 impacts disease progression over time. This innovative approach could not only increase the likelihood of detecting a therapeutic effect but also sets a new standard for how neurodegenerative diseases are studied in clinical trials.

The Financial Foundation for a Breakthrough

Bringing a novel drug through clinical trials is an enormously expensive undertaking, and a major challenge for smaller biotech companies. Herantis has been methodically building a strong financial and strategic foundation for the HER-096 program. The company reports that over 50% of the funding required for the Phase 2 study has already been secured or identified.

A cornerstone of this funding is a prestigious €8 million grant from the European Union's Horizon Europe program, awarded earlier this year. This non-dilutive funding is a powerful external validation of the project's scientific merit and potential impact. The program has also received prior financial backing from The Michael J. Fox Foundation and Parkinson's UK, two of the world's leading patient and research advocacy organizations. While the company continues to explore options like strategic partnerships and equity financing to secure the remaining funds, the existing support provides a substantial runway to initiate this pivotal study.

Antti Vuolanto, CEO of Herantis Pharma, expressed his confidence in the path ahead. “The successful outcome of our FDA meeting is an important milestone as we advance HER-096 towards Phase 2 development,” he stated. “Together with our positive Phase 1b data, encouraging biomarker findings and Horizon Europe grant support, the FDA feedback strengthens our confidence in the program and our development strategy. We look forward to initiating the study and generating data that will further evaluate HER-096's potential as a disease-modifying treatment for Parkinson's disease.”